Genomic Prediction, Inc., a Hackettstown-based leader in advanced preimplantation genetic testing, has announced the appointment of Santiago Munné, as chief scientific officer. The hire represents a major milestone for the company as it seeks to scale its “polygenic” embryo screening technology under the guidance of one of the field’s most storied pioneers.
Munné brings over 30 years of clinical and entrepreneurial experience to the firm. He is widely credited with developing the very first PGT-A (Preimplantation Genetic Testing for Aneuploidy) in 1993, a breakthrough that fundamentally changed IVF by allowing doctors to screen embryos for chromosomal abnormalities before transfer.
Munné’s career has been defined by “firsts” in the lab that translated into global standards of care. His contributions include:
- The First PGT-SR: Screening for chromosomal translocations.
- Whole Genome Sequencing (WGS): Developing methods to detect de novo mutations in embryos.
- Commercial Leadership: Co-founded Reprogenetics (the first global commercial PGT lab) and CooperGenomics.
- Automation: Most recently co-founded Overture Life, which achieved the first successful births using automated sperm injection (ICSI).
“Santiago Munné is one of the most influential scientists in reproductive genetics,” Kelly Ketterson, CEO of Genomic Prediction said. “His ability to move breakthrough science into clinical reality makes him uniquely suited to lead our scientific vision.”
At Genomic Prediction, Munné will oversee the expansion of the LifeView® platform and its proprietary Embryo Health Score™ (EHS). Unlike traditional tests that look for single-gene disorders (PGT-M) or missing chromosomes (PGT-A), EHS utilizes Polygenic Risk Scores (PRS) to assess the cumulative risk of complex, adult-onset conditions.
The platform allows parents to screen for predispositions to conditions such as:
- Cardiovascular Disease
- Type 1 and Type 2 Diabetes
- Certain Cancers (e.g., breast and prostate)
- Mental Health Conditions
Munné’s appointment comes as the IVF industry increasingly shifts toward personalized medicine. By ranking embryos based on their long-term health potential, Genomic Prediction aims to provide patients with more than just a successful pregnancy, but a deeper understanding of future health risks.
“I look forward to building upon our presence in the region and delivering meaningful results for our clients,” Munné said of his new role. He is expected to receive the 2026 Distinguished Clinician Award from the AAAAI later this month in Philadelphia, further cementing his status as a leader in the global scientific community.
